GALAPAGOS GENOMICS WKN: A0EAT9 ISIN: BE0003818359 Kürzel: GLPG Forum: Aktien Thema: Hauptdiskussion

Sehe ich das richtig? Cash 4,4 Mrd MK 2,8 Mrd Keine Schulden ?

Galapagos GAAP EPS of -€0.16, revenue of €410.2M https://seekingalpha.com/news/3901452-galapagos-gaap-eps-of-016-revenue-of-4102m?utm_source=feed_news_all&utm_medium=referral • Galapagos press release (NASDAQ:GLPG): 9M  GAAP EPS of -€0.16. • Revenue of €410.2M (+29.0% Y/Y). • Clear path forward for accelerated growth and value creation • Reshape innovation model and build fit-for-purpose organization in key strategic therapeutic areas: immunology and oncology • Jyseleca® 2022 net sales guidance further increased to €80-€90 million from €75-€85 million at H1 2022. • Cash and current financial investments of €4.4 billion on 30 September.

Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results https://www.globenewswire.com/news-release/2022/11/03/2548247/0/en/Galapagos-announces-strategy-to-accelerate-innovation-and-reports-strong-third-quarter-2022-results.html

Galapagos receives positive CHMP opinion for Jyseleca® European label update based on testicular function safety data from MANTA/RAy studies https://www.globenewswire.com/news-release/2022/10/03/2527295/0/en/Galapagos-receives-positive-CHMP-opinion-for-Jyseleca-European-label-update-based-on-testicular-function-safety-data-from-MANTA-RAy-studies.html

First key steps in pipeline rebuild and strong commercial progress in H1 2022 https://www.globenewswire.com/news-release/2022/08/04/2492746/0/en/First-key-steps-in-pipeline-rebuild-and-strong-commercial-progress-in-H1-2022.html

Galapagos to acquire CellPoint and AboundBio to accelerate access to next-generation cell therapies "https://www.globenewswire.com/news-release/2022/06/21/2466613/0/en/Galapagos-to-acquire-CellPoint-and-AboundBio-to-accelerate-access-to-next-generation-cell-therapies.html • Potential for paradigm shift in CAR-T therapy with CellPoint’s decentralized point-of-care manufacturing model, in partnership with Lonza, and AboundBio’s cutting-edge fully human antibody-based capabilities, providing a platform of next-generation CAR-Ts and bispecific antibodies • Clinical validation of decentralized production platform with CD19 CAR-T in 2 Phase 1/2a studies in relapsed/refractory Non-Hodgkin’s-Lymphoma (rrNHL) and Chronic Lymphocytic Leukemia (rrCLL) ongoing, with topline results expected in H1 2023 • Positions Galapagos in next-generation cancer therapy market and significantly broadens portfolio and capabilities • All cash acquisition of CellPoint for an upfront amount of €125 million, with milestone payments up to €100 million and AboundBio for $14 million  Webcast presentation tomorrow, Wednesday, 22 June 2022, at 14.00 CET / 8 AM ET, www.glpg.com ...

https://www.businesswire.com/news/home/20220524005319/en/Galapagos-In-licenses-Novel-Drug-Targets-for-Inflammatory-Bowel-Disease-Discovered-by-Scipher-Medicine%E2%80%99s-Spectra%E2%84%A2-Platform

RBC Expects Business Development To Unlock This Pharma Stock's Balance Sheet Value https://www.benzinga.com/general/biotech/22/05/27086970/rbc-expects-business-development-to-unlock-this-pharma-stocks-balance-sheet-value ... • Business Development primarily involves deals or collaborations around early-stage assets rather than later-stage or large acquisitions and openness to indications outside of areas GLPG has worked historically.  • RBC senses a collaborative tone towards partner Gilead Sciences Inc (NASDAQ:GILD), though it believes the deal structure between the parties may need some tuning for optimal value creation.  • With the strategic review of the internal and external pipeline still evolving, the analysts expect shares to trade in line.  • The analysts raised the price target to $62 from $60 on model updates. ...

https://www.glpg.com/press-release/3599/galapagos-demonstrates-regulatory-and-commercial-progress-in-q1-2022

https://www.streetinsider.com/dr/news.php?id=19828975&gfv=1 Galapagos NV (GLPG) Announces Jyseleca Approved in Japan Galapagos NV (NASDAQ: GLPG) reports that Gilead Sciences K.K. (Tokyo, Japan), Eisai Co., Ltd. (Tokyo, Japan) and EA Pharma Co., Ltd. (Tokyo, Japan) today announced the approval by the Japanese Ministry of Health, Labour and Welfare (MHLW), of a second indication for Jyseleca (filgotinib), a once-daily, oral, JAK1 preferential inhibitor, for the treatment of patients with moderate-to-severe active ulcerative colitis (UC). ...

Galapagos 2021 results set stage for future growth https://finance.yahoo.com/news/galapagos-2021-results-set-stage-210100025.html ... Financial results in 2021: • Group net revenues of €484.8 million as compared to €478.1 million in 2020 • Operating loss of €165.6 million as compared to €178.6 million in 2020 • Net loss of €103.2 million as compared to €305.4 million in 2020 • Cash and current financial investments of €4.7 billion on 31 December 2021 • Operational cash burni of €564.8 million, within the guided range ...

Galapagos appoints Paul Stoffels as Chief Executive Officer https://www.globenewswire.com/news-release/2022/01/26/2373804/0/en/Galapagos-appoints-Paul-Stoffels-as-Chief-Executive-Officer.html Galapagos creates 1M subscription rights https://seekingalpha.com/news/3792170-galapagos-creates-1m-subscription-rights-stock-rises-9 Galapagos (NASDAQ:GLPG) said its supervisory board created 1M subscription rights under a new plan for the benefit of a company personnel. The subscription rights have an exercise term of eight years and an exercise price of €50. Paul Stoffels will ultimately become the new subscription right holder under the scheme.

https://www.globenewswire.com/news-release/2021/11/15/2334506/0/en/Jyseleca-filgotinib-approved-in-the-European-Union-for-the-treatment-of-ulcerative-colitis.html Jyseleca®▼(filgotinib) approved in the European Union for the treatment of ulcerative colitis ...announced today that the European Commission has granted marketing authorization for Jyseleca® (filgotinib 200mg tablets) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).

Wird bestimmt bald was kommen in Sachen CEO

Neuer CEO und CSO dann up....

Galapagos reports commercial and operational progress at Q3 financial results https://www.globenewswire.com/news-release/2021/11/04/2328165/0/en/Galapagos-reports-commercial-and-operational-progress-at-Q3-financial-results.html • First nine months 2021 financial results: • Group revenues of €317.9 million • Operating loss of €175.7 million • Net loss of €119.6 million • Cash and current financial investments of €4.9 billion on 30 September 2021 • Filgotinib launch in RA on track with reimbursement secured in 14 countries • Reduced 2021 cash burn guidance by €50 million to €530-€570 million ...